Uses and limitations of fdg positron emission tomography in patients with head and neck cancer
- 1 June 1999
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 109 (6) , 880-885
- https://doi.org/10.1097/00005537-199906000-00007
Abstract
Objective: Numerous authors have reported the potential usefulness of positron emission tomography (PET). These studies have had conflicting results, at least partly owing to limited sample sizes. The objective of this study is to define not only the uses, but also the limitations of PET in patients with head and neck cancer. Study Design: Nonrandomized, retrospective analysis of PET at an academic institution. Methods: The authors performed 146 PET scans on 133 patients with head and neck cancer. Eighteen patients (19 PET scans) with thyroid disorders were excluded. A minimum 1 year of follow‐up was available in 84 patients, who were separated into groups based on whether the PET was used to detect unknown primary cancers (n = 20), stage neck nodal and distant metastases (n = 8), monitor response to nonsurgical therapy (n = 22), or detect recurrent or residual cancers (n = 34). The results of PET were compared with results from computed tomography (CT) and magnetic resonance imaging (MRI) performed in the same patients. Results: Of the unknown primary cancers, PET correctly identified 7 of 20 primary sites, giving a sensitivity of 35%. When combined with CT or MRI, the sensitivity increased to 40%. When used for detection of metastatic disease, PET demonstrated five of five nodal metastases (100%) and two of four distant metastases (50%). In evaluating the response to nonsurgical therapy, PET had a sensitivity of 50% and a specificity of 83% for detecting tumor at the primary site and a sensitivity of 86% and a specificity of 73% for detecting nodal disease. When used for evaluation of recurrent/residual disease, PET identified seven of seven cases of local recurrences/residual disease and had a specificity of 85%. PET also detected seven of seven cases of nodal disease and had a specificity of 89%. Conclusions: For staging purposes, PET is limited by its lack of anatomic detail. However, PET compares favorably with CT and MRI in detecting recurrent/residual cancers. PET imaging complements the more traditional imaging modalities (CT or MRI), especially for an unknown primary cancer. Key Words: Head and neck cancer, squamous cell carcinoma, positron emission tomography, unknown primary cancer, cervical lymph node metastasis.Keywords
This publication has 14 references indexed in Scilit:
- FDG PET in head and neck cancer.American Journal of Roentgenology, 1997
- Detection of Cervical Metastasis: A Meta-analysis Comparing Computed Tomography With Physical ExaminationJAMA Otolaryngology–Head & Neck Surgery, 1997
- Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT.Radiology, 1996
- The Role of FDG-PET in the Preoperative Assessment of N-Staging in Head and Neck CancerActa Oto-Laryngologica, 1996
- A comparative diagnostic study of head and neck nodal metastases using positron emission tomographyThe Laryngoscope, 1995
- The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patientsThe Laryngoscope, 1995
- Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation.Radiology, 1993
- Positron emission tomography: A new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathyThe Laryngoscope, 1992
- Cervical metastases from unknown primaries: Radiotherapeutic management and appearance of subsequent primariesInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Metastatic cervical adenopathy from tumors of unknown origin: the role of CT.Radiology, 1984